eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2013
vol. 8
 
Share:
Share:
Editorial

Autoimmune diseases of gastrointestinal tract in children with humoral immunodeficiency – problems of diagnosis

Anna Pituch-Noworolska

Prz Gastroenterol 2013; 8 (4): 218–224
Online publish date: 2013/09/09
Article file
- Autoimmune diseases.pdf  [0.13 MB]
Get citation
 
PlumX metrics:
 

The most common humoral immunodeficiencies in children

Selected IgA deficiency (sIgAD, IgAD)



The frequency of this defect is unknown; estimation of its occurrence from 1 : 400 to 1 : 700 children depends on the country of the study and number of children included in the study group [1]. The majority of children (about 80%) have no clinical symptoms of selected IgA deficiency. The remaining children show recurrent infections of the respiratory and gastrointestinal system. Abdominal pain, problems with jejunum motility (constipation or diarrhea), feeling of discomfort and distention are 10–20 times more frequent in sIgAD than in healthy children in the same age. The lack of secretory IgA produced and secreted by B lymphocytes present in free lymphoid tissue under mucous membrane of the gastrointestinal tract is associated with these symptoms [2–4]. The basic role of secretory IgA is protection of mucous membranes and selection of antigens passing this barrier. Moreover, the secretory IgA inhibits the expression of proinflammatory bacterial epitopes, limiting the presence of bacterial pathogens to special determined regions of the jejunum mucous membrane, preventing the binding of pathogens to epithelial cells and helping in intraepithelial neutralization of pathogens and other bacterial products [5]. In selected IgA deficiency this immunoglobulin is replaced by IgG and IgM. The lack of secretory IgA is associated not only with prolonged inflammatory diseases of the gastrointestinal tract such as atrophic gastritis, Crohn’s disease or celiac disease but also with infections, e.g. Helicobacter pylori, Campylobacter or Giardia lamblia, showing similar symptoms. These infections are more frequent in adults with sIgAD than in children. In the histology of biopsy from people during Helicobacter pylori or Campylobacter infection, the flattening of jejunum villi suggests celiac disease. However, the effective therapy of infection with antibiotics leads to regeneration of villi, but in some patients these infections are prolonged so the destruction of the jejunum mucous membrane is irreversible due to chronic diarrhea. IgA helps in elimination of pa­thogens from the surface of mucous membrane epithelial cells so the lack of this immunoglobulin may maintain infection by facilitating the binding of pathogens to the surface of epithelium [1, 2]. The prevalence of celiac disease in children with sIgAD and familiar occurrence of both diseases suggested a common genetic background of both diseases. Moreover, the haplotype of HLA: A1, Cw7, B8, DR3, DQ2 is important for co-existence of IgAD and celiac disease [2, 6]. However, the precise analysis of frequency of celiac disease within the IgAD population does not support this hypothesis because the co-existence of celiac disease and sIgAD is lower than expected based on the effect of a common genetic background. Another hypothesis of association of celiac disease and IgAD proposes an increase of B lymphocyte stimulating factors (B-lymphocyte stimulator (BLyS) and a proliferation inducing ligand – APRIL) noted in IgAD patients as an important factor. A new, large, in-depth study did not reveal differences between the level of these factors in IgAD with or without concomitant celiac disease [7]. It seemed, that the possibility of destruction of the mucous membrane and occurrence of clinical symptoms due to disturbed metabolism of gliadin in the case of a lack of secretory IgA is more probable [2]. In the histology of biopsy in celiac disease the pattern of changes in the jejunum is similar in patients with or without IgAD. A gluten-free diet (GFD) is effective, despite sIgAD.

The frequency of Crohn’s disease and ulcerative colitis in people with IgAD is unknown [2, 8–11]. Moreover, in adults with IgAD, nodular lymphoid hyperplasia (NLH) is described as a separate clinical entity. The high amounts of large nodules consisting of B lymphocytes producing mainly IgM, located along mucous membrane of the gastrointestinal tract, lead to symptoms of malabsorption, flattening of villi, and even jejunum occlusion [2]. The differential diagnosis of inflammatory/autoimmune disease of GI in sIgAD patients is very difficult because of overlapping of clinical symptoms and similar changes in histology of jejunum biopsy.



Common variable immunodeficiency



Common variable immunodeficiency (CVID) was primarily described in adults, so the majority of data about the clinical symptoms and course, clinical symptoms

in concomitant diseases, are based on observations from adult patients. The frequency of CVID is be­tween

1 : 25000 and 1 : 50000. Diagnosis is based on exclusion of known causes of noted clinical symptoms and hy­pogammaglobulinemia. Criteria of CVID are lower level of IgG only or IgG and a second immunoglobulin (IgA or IgM), low level of specific antibodies to vaccination antigens, and disorders in cellular immunity in marked percentage of patients. A lower number of T lymphocytes, adverse proportion between CD4 and CD8 subpopulations, and low proliferation indexes after mitogen and antigen stimulation are observed [1, 2, 11–13]. Clinical symptoms of CVID are different in children and adults [14]. In patients diagnosed as adults chronic sinusitis, bronchiectasis, and chronic lung disease are often observed, while in children diagnosed with CVID these symptoms are very rare. Measurement of immunoglobulin levels in children is due to frequent infections of the respiratory tract, otitis, sinusitis (in older children) characterized by prolonged course, and weak response to antibiotics. Low levels of immunoglobulins (according to age-related level) and no increase in response to infection are the basis of humoral immunodeficiency diagnosis – common variable immunodeficiency (CVID).

Autoimmune diseases occurred in 20–30% of CVID patients as hematological symptoms, mainly thrombocytopenia, leukopenia, and neutropenia [9, 15]. After he­matological symptoms, autoimmune and chronic inflammatory diseases of the gastrointestinal tract, e.g. Crohn’s disease, celiac disease, atrophic gastritis with megaloblastic anemia, autoimmune hepatitis, ulcerative colitis and nodular lymphoid hyperplasia (NLH), are noted in these patients [2, 5, 11, 16, 17]. This sequence of autoimmune diseases in CVID (first – haematological symptoms, second – GI tract, other – less frequent) is based on data from adult patients. There are a few observations from children about co-existence of auto­immunity and CVID. Thrombocytopenia, neutropenia, hemolytic anemia and gastrointestinal tract disease (inflammatory bowel disease – IBD, celiac disease) are frequent in children but the proportions between them and frequency of particular diseases are not known. Autoimmunity of the gastrointestinal tract in children with CVID is second in frequency after hematologic symptoms, like in adults. However, in children with CVID celiac disease, Crohn’s disease and hepatitis are common while in adults rheumatoid arthritis, skin diseases, systemic lupus erythematosus, primary biliary cirrhosis, pernicious anemia, and atrophic gastritis are more

frequent [2]. The diagnosis of autoimmune disease in­cludes clinical symptoms and circulating antibodies for described cellular and tissue antigens. In CVID the serological diagnosis is problematic because of 2 reasons: first, low production of specific antibodies typical for humoral immunodeficiency; and second, lack of gA in IgAD and in some CVID patients. In autoimmune/inflammatory disease of the GI tract antibodies in IgA class were clinically significant as a consequence of IgA’s role in GI mucous membranes. Considering the results of antibody detection as significant for diagnosis in IgA class only, in the case of CVID patients may lead to false negative results. Now, tests detecting antibodies are performed in both (IgA and IgG) classes of immunoglobulins as routine. Moreover, the histology of the jejunum in IBD in patients with IgAD and CVID shows some differences as compared to IBD histology in patients without immunodeficiency. It seems that disturbances in B lymphocyte ontogeny in CVID, e.g. abnormal process

of maturation, incomplete hypermutation, lack or low number of B memory cells, are associated with a different pattern of histology of tissues involved in the au­toimmune process [2, 17, 18]. In jejunum biopsy from patients with CVID and celiac disease or Crohn’s disease the number of B lymphocytes in the infiltration is low, and plasmocytes are singular or absent. This different histology is so typical and characteristic for CVID pa­tients that these diseases are called celiac-like disease and Crohn’s-like disease to discriminate between patients with or without immunodeficiency [2].



Deficiency of specific antibody synthesis



In this deficiency the level of immunoglobulin is within the normal range but the clinical course of infections suggests a deficiency. The most common infections such as tonsillitis, pharyngitis, and bronchitis become severe, almost septic in otherwise healthy children. Levels of IgG and subclasses of IgG are within the normal range, and parameters of cellular immunity are without disorders. The immunodeficiency is diagnosed based on the low level of specific antibodies to vaccination antigens only [2, 9]. The low level of specific antibodies suggests disorders of their production and is the main symptom of this immunodeficiency. Similar to CVID, this type of immunodeficiency is an indication for regular immunoglobulins’ substitution [12].



Immunoglobulins’ substitution



The regular substitution of immunoglobulins in a dose of 0.4–0.5 g/kg b.w./month intravenously or subcutaneously delivers the specific antibodies to common pathogens. Decrease in frequency and milder clinical course of infections are the main goals to obtain with immunoglobulins’ substitution. In the case of IBD in CVID the regular substitution is effective in prophylaxis of infections but has no influence on the course of concomitant autoimmune/inflammatory GI disease. One plausible explanation indicated lack of possibility to reach the epithelial jejunum surface by immunoglobulin molecules [2]. However, in other autoimmune diseases co-existing with CVID, e.g. chronic thrombocytopenia or neutropenia, regular substitution increased the number of platelets or neutrophils in CVID patients, although the low dose of IgG is below the proved suppressive effect on the autoimmune process [2]. It might be the effect of anti-inflammatory activity of IgG, even in a pro­phylactic dose. The suppressive effect of immunoglobulin infusion is associated with a high dose (1.0–2.0 g/kg b.w./therapy). This high-dose therapy is recommended in acute thrombocytopenia (e.g. associated with viral infection), Kawasaki disease, chronic polyneuropathy with demyelinization, hemolytic anemia and others 12].

Diagnosis of gastrointestinal tract autoimmune diseases

Standards of autoimmunity of GI diagnostic procedures



The standard diagnosis of GI autoimmunity is performed in people with clinical symptoms and consists of laboratory tests (detection of autoantibodies), imaging procedures (gastroscopy, colonoscopy and other radiological methods) and histology of jejunum mucous me­mbrane biopsy [19–21]. The laboratory markers are helpful in early diagnosis preceding the onset of severe clinical symptoms in many patients. In recent years, the detection of antibodies associated with the GI autoimmune process is commonly used for screening in the risk group of children including humoral immunodeficiencies (IgAD, CVID).



Antibodies



Celiac disease



Typical clinical symptoms for celiac disease are observed in about 20% of patients (classic form of disease) [22]. In the remaining patients, clinical symptoms suggest jejunum dysfunction and malabsorption syndrome leading to hypochromic anemia, occurrence of aphthae and aphthous stomatitis, osteopenia, sometimes osteoporosis with bone fractures, low level of iron resistant to oral therapy, and hypoproteinemia. These symptoms are not directly associated with the gastrointestinal tract. Diagnosis of latent, silent or atypical form of celiac disease, often in older children, teenagers and adults, is based on complex procedures. The genetic background of celiac disease is associated with expression of HLA-DQ2 and HLA-DQ8 determinants, which explains the familiar predisposition to this disease. Commonly used antibodies tested during diagnostic procedures for celiac disease include antibodies against gliadin, tissue transglutaminase and endomysium. Antibodies in IgA class are clinically significant with the exception of IgAD and CVID with IgA deficiency, when antibodies in IgG class are significant. Now, there are commercial tests offering assays in both classes of immunoglobulins [23–25].

Antibodies to gliadin are detected with indirect fluorescence in serum diluted 1 : 10 in both IgG and IgA immunoglobulin classes. Sensitivity and specificity of this test are 100% in IgG and 95–99% in IgA. Gluten-free diet (GFD) resulted in a decrease of antibody levels within

3–6 months, often below the detection level [23, 24].

Endomysial antibodies are associated with complex gliadin-reticulin and tissue transglutaminase facilitating complex formation. Indirect fluorescence with serum diluted 1 : 10 is the best method. The serial dilution of positive serum is a semi-quantitative assay of antibody levels which is used for monitoring GFD effects. Sensitivity and specificity of these antibodies are 100% in IgA class, lower in IgG class [23, 24].

Antibodies against tissue transglutaminase are assayed with the ELISA quantitative method in IgA and IgG class, which is important for IgAD patients with celiac disease. Sensitivity is estimated as 96%, specificity as 98% [23, 24].



Crohn’s disease



Antibodies against tissue transglutaminase are noted not only in serum of celiac patients but in about 20% of patients with Crohn’s disease. Now, antibodies against Saccharomyces cerevisiae antigens (ASCA) are used as the most typical and specific for Crohn’s disease. The quantitative method (ELISA) is commonly used as more precise and objective than the previously used qualitative method (indirect fluorescence). Antibodies in IgA class are clinically significant, but for people with IgAD or CVID without IgA, antibodies in IgG class are significant. Specificity of ASCA antibodies is estimated as 99%, sensitivity as 79%.

Indirect fluorescence is used for detection of antibodies against exocrine pancreas tissue (PAB) and product of pancreatic cells (drop like fluorescence). Specificity of these antibodies for diagnosis of Crohn’s disease is about 93%, and the predictive value compared to ASCA about 77% [26].



Ulcerative colitis



The detection of antibodies in serological diagnosis of ulcerative colitis (UC) has been used for a few years. Antibodies against mucin produced by goblet cells (GAB), against neutrophil myeloperoxidase (ANCA) and antinuclear (ANA) are assayed with indirect immunofluorescence or ELISA. The GAB are noted in about 80% of patients with UC.



Jejunum histology



In celiac disease changes in the jejunum are classified according to the Marsh, Oberhuber and Corazza scale [24]. The most common Marsh scale includes the number of intraepithelial lymphocytes (IEL), proportion of crypt number and villi height, and structure and height of villi. Patients with clinical symptoms and a positive serological test but without changes in jejunum villi parameters are problematic (Marsh scale 0) [27]. In these patients the electron microscopy seemed to be a resolution and changes seen at microscopic level are diagnosed as microscopic enteritis [28, 29].

The typical pattern in chronic inflammatory bowel disease consisted of infiltration, development of new lymphoid nodules, and increase of IEL number. In celiac disease the infiltrations consist of T and B lymphocytes, plasmocytes and a few monocytes. Interesting was the high percentage of TCR / lymphocytes within T lymphocytes infiltrating the submucous level of the jejunum wall. The high number of TCR / was higher when celiac disease occurred in IgAD patients [30]. In celiac disease infiltrations are free from neutrophils often noted in infiltrations typical for Crohn’s disease and UC. Presence of given cell populations within infiltrations is associated with different profiles of cytokines, mainly proinflammatory, produced locally. Production of antibodies by B cells present in infiltrations is induced by antigens present in close contact with immunocompetent cells, e.g. neutrophils dying in situ, which leads to production of ANA and ANCA [20, 21].



Celiac disease in immunodeficiency



Diagnosis of celiac disease in humoral immunodeficiency is difficult because of scanty and unspecific symptoms and because of overlapping of these symptoms, e.g. periodic or prolonged diarrhea, and abdominal pain caused by IgAD only, without concomitant celiac disease [31, 32]. In children without immunodeficiency anti-endomysial antibodies, antibodies to gliadin and tissue transglutaminase are produced mainly in IgA class (im­munoglobulin of mucous membrane). These same antibodies are produced in IgAD patients but in IgG class. In patients with CVID, the problem of antibody production is more complex due to IgA deficiency in a marked number of patients and weak production of antibodies in response to antigens including autoantigens. However, permanent presence of autoantigens in contact with immunocompetent cells may be strong enough for induction of antibody production, despite weaker function of the immune system. The level of these antibodies is above the limit of a positive value, but lower than observed in children without immunodeficiency.

Standard diagnostic procedures in celiac disease consisted of serological tests detecting typical antibodies in serum in patients with clinical symptoms suggesting celiac disease and histology of jejunum biopsy. In some patients, despite typical clinical symptoms, the histology of the jejunum is negative [22, 27]. Submicroscopic study helps in individual cases showing very delicate but typical changes [29]. Following this, clinicians suggest GFD when the clinical symptoms are present without histological proof of celiac disease in typical analysis of biopsy. Moreover, the submicroscopic changes are also an indication for GFD [29].

Observations of GFD effects in patients with CVID showed resistance to this therapy in about 20% of pa­tients. Within this group of CVID patients lack or very low level of IgA was frequent. Jejunum dysfunction and malabsorption syndrome progress despite restricted GFD, leading to inhibition of growth and development of malnutrition.



Crohn’s disease and UC in immunodeficiency



Adults with CVID and gastrointestinal involvement demonstrate chronic diarrhea in about 10% to 50% of patients [2, 8, 12, 16, 18]. In children with IgAD, CVID diarrhea is less frequent but studied groups were small. The bowel inflammatory disease in immunodeficient pa­tients demonstrated different histology often compared to lymphocytic colitis than typical Crohn’s disease or UC [2]. Regular substitution of immunoglobulins does not inhibit progress of inflammation, and does not help in regeneration and healing of mucous membrane damage. Hypotheses explaining the lack of effects of immunoglobulins' substitution are various, including defect of regulatory T lymphocytes (Treg CD4/CD25/FoxP3), ef­fects of different profiles of proinflammatory cytokines produced locally and, what seemed to be most interesting, lack of possibility to reach the surface of the epithelium by immunoglobulins given intravenously. This phenomenon is important in patients with CVID and a low level or lack of IgA [2].

In histology of jejunum from patients with CVID and IBD, the cellular infiltrations consisted mainly of T lymphocytes with a low number of B lymphocytes and few or no plasmocytes [2, 12]. Diagnosis of UC is often difficult in patients without immunodeficiency so this diagnosis in patients with CVID is much more problematic.

In a study including 248 patients (children and adults) with CVID, UC was noted only in 7 patients. However, in 10 other patients demonstrating clinical symptoms of inflammation the final diagnosis was not established. It showed the difficulties in differential diagnosis of jejunum diseases in immunodeficient patients [11].



Differential diagnosis – “collagenous sprue”, microscopic and autoimmune, chronic bowel

inflammation




Collagenous sprue (CS) is a rare, severe disorder of jejunal function (absorption process mainly) with a low number of crypts, flattening of villi, and collagen de­posits under the epithelial cell layer containing cellular elements within. This histology is typical for diagnosis of CS [33]. However, similar symptoms, e.g. histology with flattening of villi, lack of response to GFD (observation during at least 1 year), are noted in refractory celiac disease (RCD), which might suggest wrong diagnosis and delay in CS diagnosis. Precise diagnosis is very important as CS is a progressive disease leading to se­vere malabsorption syndrome, cachexia and death. Therapy is based on steroids, immunosuppression and total parietal nutrition [32]. Up to now this disease has been noted in patients without immunodeficiency, although CS symptoms overlapping diet refractory celiac disease with cachexia may suggest CS in these patients.

Autoimmune enteropathy (AE) was separated as a new entity in young children with chronic diarrhea and antibodies to epithelial cells (anti-enterocyte antibodies) as a marker of the autoimmune process. The first case was described in a child with IgAD, which suggests the association between AE and immunodeficiency. The majority of patients were boys diagnosed in the first year of life [28]. Anti-enterocyte antibodies seemed to be important for induction and supporting the process of jejunum mucous damage but it has not been proved yet. However, in other prolonged inflammatory diseases, e.g. Crohn’s, celiac disease or UC, these antibodies are absent, supporting the idea of a separate diagnostic and clinical entity [28].

Microscopic enteritis (ME) was used first in adults showing malabsorption symptoms without inflammation characteristics, without changes in villi structure or ulcers present in light microscopy [29]. Such enteritis might explain symptomatic celiac disease without changes in jejunum mucous (Marsh scale 0) due to overlapping symptoms [24, 27, 29]. Differentiation between these two syndromes is possible with electron microscope assay. Submicroscopic changes are more typical for celiac disease with minimal mucous damage (Marsh 0).

Algorithm of differential diagnosis in children with immunodeficiency

Children with immunodeficiency and gastrointestinal tract involvement demonstrate abdominal pain, meteorism, feelings of discomfort, lack of appetite, periodic diarrhea or constipation. In other children without gastric symptoms the inhibition of growth and underweight are noted, suggesting discrete malfunction of the jejunum. High prevalence of gastrointestinal autoimmune diseases in this group of children is an indication for a screening test of typical autoantibodies in serum. Observations of preserved autoantibodies’ production in immunodeficiency such as CVID and IgAD modify the common view about the possibility of the immune system to respond to antigens. Studies of antibody production are focused on vaccination antigens given 2 or 3 times in a single dose in precise periods of time. The low function of memory in CVID or disorders of specific antibody synthesis resulted in low titers of specific antibodies. In the autoimmune process, autoantigen is present permanently in contact with immunocompetent cells, stimulating them effectively to production of antibodies. The final level of antibodies in serum is often lower than in children without immunodeficiency. In consequence of this the limit of a positive result should be lowered. Considering low levels of antibodies as positive results, children with a probable autoimmune process are selected for further tests, repeating the antibody assay after 4–6 months, with careful clinical observations, undertaking diagnostic procedures without delay [34]. Presence of antibodies, even at low levels, and discrete, unspecific clinical symptoms are indications for a diagnostic procedure including histology of jejunum biopsy without repeating the antibody assay.

In celiac disease diagnosed in children with IgAD, restricted GFD is effective as in children without IgAD. In CVID the response to GFD in the majority of patients is good but in about 20% of patients resistance to GFD and progress of symptoms are noted. The course of disease in these patients is severe, and time to obtain remission is longer. Therapy with steroids, monoclonal antibodies against TNF and immunosuppression might be effective.

Crohn’s disease is more frequent than UC in children with immunodeficiency. Untypical clinical course results in delay of diagnostic procedures. Antibodies detected before severe clinical symptoms signal the autoimmune process and, in consequence, introduction of therapy which diminishes the development of malabsorption syndrome and jejunum damage. Regular substitution of immunoglobulins in CVID prevents infections and protects patients during steroid or immunosuppressive therapy for Crohn’s disease or UC.



Our observations



Detection of antibodies typical for Crohn’s disease and celiac disease was performed in 43 children diagnosed with CVID and 63 children with IgAD. Antibodies typical for celiac disease (against endomysium tissue transglutaminase and gliadin) were noted in 14 children (3 diagnosed with CVID, 11 with IgAD). Two of them were diagnosed as celiac despite weak and unspecific clinical symptoms. Antibodies typical for Crohn’s disease were noted in 16 children (7 diagnosed with CVID, 9 with IgAD). The titer of antibodies was close to 20 units (border level for a positive result) but because of immunodeficiency was considered as positive followed with cli-nical careful observations and monitoring antibodies every 4–6 months.

Based on our observations and results of the study we suggest that in patients with immunodeficiency and gastrointestinal symptoms indicating an autoimmune or inflammatory process, the diagnostic procedures and therapy may need modifications of general standard methods and working out new standards.

Acknowledgments

The study was supported by project K/ZDS/001479 (Medical College, Jagiellonian University).

References

 1. Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev 2009; 22: 396-414.

 2. Agarwal S, Mayer L. Pathogenesis and treatment of gastrointestinal disease in antibody deficiency syndromes. J Allergy Clin Immunol 2009; 124: 658-64.

 3. Arkwright PD, Abinun M, Cant AJ. Autoimmunity in human primary immunodeficiency diseases. Blood 2002; 99: 2694-702.

 4. Collin P, Maki M, Keyrilainen O, et al. Selective IgA deficiency and coeliac disease. Scand J Gastroenterol 1992; 27: 367-71.

 5. Kobrynski LJ, Mayer L. Diagnosis and treatment of primary immunodeficiency disease in patients with gastrointestinal symptoms. Clin Immunol 2011; 139: 238-48.

 6. Valletta E, Fornaro M, Pecori S, et al. Selective immunoglobulin A deficiency and celiac disease. J Invest Allergol Clin Immunol 2011; 21: 242-4.

 7. Fabris M, De Vita S, Visentini D, et al. B-lymphocyte stimulator and a proliferation-inducing ligand seru levels in IgA-deficient patients with and wtihout celiac disease. Ann N Y Acad Sci 2009; 1173: 268-73.

 8. Agarwal S, Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency. Curr Allergy Asthma Rep 2009; 9: 347-52.

 9. Arason GJ, Jorgensen GH, Ludviksson BR. Primary immunodeficiency and autoimmunity. Scand J Immunol 2010; 71: 317-28.

10. Branth D, Gershwin ME. Common variable immune deficiency and autoimmunity. Autoimm Rev 2006; 5: 465-70.

11. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency. Clin Immunol 1999; 92: 34-48.

12. Cunningham-Rundles C. How I treat common variable immu­ne deficiency. Blood 2010; 116: 7-15.

13. Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVID) and the management of patients with these conditions. Br J Haematol 2009; 145: 709-27.

14. Glocker E, Ehl S, Grimbacher B. Common variable immunodeficiency in children. Curr Opinion Pediatr 2007; 19: 685-92.

15. Boileau J, Mouillot G, Gerard L, et al. Autoimmunity in common variable immunodeficiency. J Autoimmunity 2011; 35: 1-8.

16. Daniels JA, Lederman HM, Maitra A, et al. Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID). Am J Surg Pathol 2007; 31: 1800-12.

17. Knight AK, Cunningham-Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev 2006; 5: 156-9.

18. Malamut G, Verkarre V, Suarez F, et al. The enteropathy associated with common variable immunodeficiency. Am J Gastro­enterol 2010; 105: 2262-75.

19. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Ann Rev Immunol 2010; 28: 573-621.

20. Stange EF, Travis SPL, Vermeiere S, et al. Europen evidence based consensus on the diagnosis and management of ulcerative colitis. J Crohn’s Colitis 2008; 2: 1-23.

21. Stange EF, Travis SPL, Vermeiere S, et al. Europen evidence based consensus on the diagnosis and management of Crohn’s disease. Gut 2006; 55 Suppl. 1: i1-15.

22. Nejad AR, Rostami K, Pourhosein Gholi MA, et al. Atypical presentation is dominant and typical for celiac disease. J Gastrointest Liver Dis 2009; 18: 285-91.

23. Evans KE, Sanders DS. What is the use of biopsy and antibodies in celiac disease. J Intern Med 2011; 269: 572-81.

24. Walker MM, Murray JA. An update in the diagnosis of celiac disease. Histopathology 2011; 59: 166-79.

25. Villalta D, Tonutti E, Prause C, et al. IgG antibodies against deamidated gliadin peptides for diagnosis of celiac disease in patients with IgA defieciency. Clin Chem 2010; 56: 464-8.

26. Demirsoy H, Ozdil K, Ersoy O, et al. Anti-pancreatic antibody in Turkish patients with inflammatory bowel disease and first-degree relatives. World J Gastroenterol 2010; 7: 5732-8.

27. Sbarbati A, Valletta E, Bertini M, et al. Gluten sensitivity and “normal” histology. Dig Liver Dis 2003; 35: 768-73.

28. Russo P, Alvarez F. Autoimmune enteropaty. Clin Appl Immunol Rev 2002; 2: 203-16.

29. Rostami K, Villanacci V. Microscopic enteritis. Dig Liver Dis 2009; 41: 245-52.

30. Borrelli M, Maglio M, Agnese M, et al. High density of intraepithelial gamma/delta lymphocytes and deposits of immuno­globulin (Ig)M anti tissue transglutaminase antibodies in the jejunum of celiac patients with IgA deficiency. Clin Exp Immunol 2009; 160: 199-206.

31. Cataldo F, Marino V, Ventura A, et al. Prevalence and clinical features of selective immunoglobulin A deficiency in coeliac disease: an Italian multicentre study. Italian Society of Paediatric Gastroenterology and Hepatology (SIGEP) and "Club del Tenue" Working Groups on Coeliac Disease. Gut 1998; 42: 362-5.

32. Cataldo F, Marino V, Bottaro G, et al. Celiac disease and selective immunoglobulin A deficiency. J Pediatr 1997; 131: 306-8.

33. Zhao X, Johnson R.L. Collagenous sprue. Arch Pathol Lab Med 2011; 135: 803-9.

34. Pituch-Noworolska A, Zwonarz K. Celiac and inflammatory bowel diseases in children with primary humoral immunodeficiency. In: Autoimmune diseases. Chan J (ed.)., Intech 2012; 151-72.
Copyright: © 2013 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.